marketshareAI

Aptamer Group

APTAHealthcare
0.3988GBX
2.26%
Market Cap
10.60M
Volume
3.32M
25% of avg
P/E Ratio
EPS (TTM)
Beta
-0.24
Day Range
0.3905p - 0.4000p
52 Week Range
0.2000p0.3988p0.6500p
0.3988p

Upcoming Events

24 July 2025
General Meeting
28 July 2025
Second Admission of the Conditional Placing Shares to trading on AIM
22 October 2025
Expected Full Year Results for the year ending 30 June 2025
High Impact Event
Q4 2025
Product launch of IHC kits containing Optimer®-Fc reagent
High Impact Event
January 2026
Anticipated commercialization of Optimer-containing vaccines
High Impact Event
Early 2026
Initial revenues from licensing agreement expected
High Impact Event
Mid-2026
Prototype ELISA assay development and validation expected to be completed
High Impact Event
2027
First commercial sales of Alzheimer's disease diagnostic test
High Impact Event
Early 2030
Estimated global market for fibrosis treatments to exceed $20 billion
High Impact Event
APTA
NEUTRAL

Aptamer Group Announces Director Dealings

The healthcare company has announced changes to its major shareholdings.

APTA
NEUTRAL

Aptamer Group Provides Update on General Meeting

The biotechnology company has announced the posting of a circular and notice of a general meeting to shareholders.

APTA
BAD

Aptamer Group Raises £2M Through Discounted Placing

The biotechnology company has raised £2 million through a discounted share placing, representing 25% dilution for existing shareholders.

APTA
NEUTRAL

Aptamer Group Unveils Liver Fibrosis Breakthrough with Optimer® Platform

The biotechnology company announces a breakthrough in its efforts to develop a targeted therapy for liver fibrosis using its proprietary Optimer® platform.

APTA
GOOD

Aptamer Group Secures Licensing Deal with Global Life Sciences Leader

The biotechnology company has secured a development and licensing agreement with a major global life sciences firm to create a custom Optimer®-Fc reagent for use in diagnostic kits, providing a new revenue stream.

APTA
GOOD

Aptamer Group Expands Unilever Partnership with Second Optimer Development Programme

The biotechnology company has secured a second development programme with a global consumer goods leader, expanding its partnership and potential revenue streams in the personal care market.

APTA
NEUTRAL

Aptamer Presents New Delivery Vehicle Data at ASGCT

The biotechnology company presents new data on its Optimer delivery platform, indicating potential for broad therapeutic application across fibrotic diseases.

APTA
GOOD

Aptamer Group Secures New Contracts and Licensing Deals

The leading developer of synthetic binders has secured new development contracts and licensing deals, signaling continued commercial traction for its Optimer platform.

APTA
GOOD

Aptamer Group's Alzheimer's test advances with ELISA format and royalty agreement

The biotechnology company has advanced its Alzheimer's disease diagnostic test, adapting it to a widely used hospital format and securing a royalty agreement with a partner.

APTA
VERY GOOD

Aptamer Group Secures Licensing Deal for Optimer Vaccine Adjuvants

The biotechnology company has secured a global licensing agreement for its Optimer binders to be used as vaccine adjuvants in the swine health sector, creating a new revenue stream.